Jazz Pharma (JAZZ) R&D head cashes in stock under preset plan
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc (JAZZ) reported that executive officer Robert Iannone, EVP, Global Head of R&D & CMO, exercised stock options and sold shares on August 27, 2026. He exercised derivative securities covering 57,500 Ordinary Shares at exercise prices of $113.10 and $137.12 per share, acquiring the same number of Ordinary Shares. On the same date, he sold an aggregate of 76,921 Ordinary Shares in multiple transactions at weighted average prices ranging from approximately $247.86 to $252.76 per share. The filing states these trades occurred automatically under a Rule 10b5-1 trading plan adopted on May 28, 2026.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
14 txns
Insider
Iannone Robert
Role
EVP, Global Head of R&D & CMO
Sold
76,921 shs ($19.21M)
Approx. gross sale proceeds
$19.21M
Approx. exercise cost
$7.24M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option (right to buy) F1, F7 | 884 | $0.00 | $0.00 |
| Exercise | Incentive Stock Option (right to buy) F1, F8 | 2,916 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) F1, F7 | 26,116 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) F1, F8 | 27,584 | $0.00 | $0.00 |
| Exercise | Ordinary Shares F1 | 26,116 | $113.10 | $2.95M |
| Exercise | Ordinary Shares F1 | 884 | $113.10 | $100K |
| Exercise | Ordinary Shares F1 | 27,584 | $137.12 | $3.78M |
| Exercise | Ordinary Shares F1 | 2,916 | $137.12 | $400K |
| Sale | Ordinary Shares F1, F2 | 18,187 | $247.8573 | $4.51M |
| Sale | Ordinary Shares F1, F3 | 11,423 | $248.6664 | $2.84M |
| Sale | Ordinary Shares F1, F4 | 18,113 | $250.0178 | $4.53M |
| Sale | Ordinary Shares F1, F5 | 19,639 | $250.6032 | $4.92M |
| Sale | Ordinary Shares F1, F6 | 9,259 | $251.9499 | $2.33M |
| Sale | Ordinary Shares F1 | 300 | $252.76 | $76K |
Holdings After Transaction:
Incentive Stock Option (right to buy) — 0 shares (Direct);
Non-Qualified Stock Option (right to buy) — 0 shares (Direct);
Ordinary Shares — 65,686 shares (Direct)
Footnotes (8)
- F1. This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
- F2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $247.29 to $248.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $248.29 to $249.24. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $249.33 to $250.325 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $250.33 to $251.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $251.37 to $252.31. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F7. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
- F8. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of May 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.
Key Figures
Options Exercised: 57,500 Ordinary Shares
Shares Sold: 76,921 Ordinary Shares
Exercise Price: $113.10 per share
+5 more
8 metrics
Options Exercised
57,500 Ordinary Shares
Total underlying shares from 4 option exercises on August 27, 2026
Shares Sold
76,921 Ordinary Shares
Aggregate shares sold in multiple open-market transactions on August 27, 2026
Exercise Price
$113.10 per share
Exercise price for certain Incentive Stock Options and Non-Qualified Stock Options
Exercise Price
$137.12 per share
Exercise price for other Incentive Stock Options and Non-Qualified Stock Options
Sale Price Range
$247.29–$252.76 per share
Weighted average sale price ranges across reported sale tranches
Rule 10b5-1 Plan Adoption Date
May 28, 2026
Date the trading plan governing these transactions was adopted
Option Expiration Date
February 26, 2030
Expiration for certain exercised options
Option Expiration Date
August 7, 2029
Expiration for other exercised options
Key Terms
Rule 10b5-1, Incentive Stock Option, Non-Qualified Stock Option, weighted average sale price, +1 more
5 terms
Rule 10b5-1 regulatory
"pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Incentive Stock Option financial
"security_title: Incentive Stock Option (right to buy)"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Non-Qualified Stock Option financial
"security_title: Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average sale price financial
"The price reported reflects the weighted average sale price."
Equity Incentive Plan financial
"These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
FAQ
What did JAZZ executive Robert Iannone report on this Form 4?
Robert Iannone reported exercising 57,500 stock options for Jazz Pharmaceuticals plc Ordinary Shares and selling 76,921 shares on August 27, 2026, in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
How many Jazz (JAZZ) options did Robert Iannone exercise and at what prices?
He exercised options covering 57,500 Ordinary Shares, including tranches at exercise prices of $113.10 per share and $137.12 per share, converting Incentive Stock Options and Non-Qualified Stock Options into Ordinary Shares of Jazz Pharmaceuticals plc.
Were Robert Iannone’s JAZZ trades made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2026, and notes that the transactions occurred automatically rather than as discretionary trades by the reporting person.
What types of stock options did Robert Iannone exercise for JAZZ?
He exercised both Incentive Stock Options and Non-Qualified Stock Options for Jazz Pharmaceuticals plc Ordinary Shares, granted under the company’s 2011 Equity Incentive Plan, with expiration dates in 2029 and 2030 as disclosed.
How many derivative transactions are reported in this JAZZ Form 4?
The Form 4 reports 4 derivative transactions, all coded M for exercises or conversions of stock options, covering a combined 57,500 underlying Ordinary Shares of Jazz Pharmaceuticals plc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
